Motzer, Robert J. http://orcid.org/0000-0001-6925-2327
Martini, Jean-François
Mu, Xinmeng J.
Staehler, Michael http://orcid.org/0000-0002-4574-6522
George, Daniel J. http://orcid.org/0000-0002-0836-8542
Valota, Olga http://orcid.org/0000-0002-7583-9914
Lin, Xun http://orcid.org/0000-0001-9882-0223
Pandha, Hardev S.
Ching, Keith A.
Ravaud, Alain
Funding for this research was provided by:
Pfizer
Memorial Sloan-Kettering Cancer Center (P30-CA008748)
Article History
Received: 4 August 2021
Accepted: 22 September 2022
First Online: 10 October 2022
Competing interests
: R.J.M. receives consulting fees from Pfizer, Eisai, Novartis, Merck, Genentech/Roche, Incyte, Lilly Oncology, EMD Serono, Aveo, and Exelixis; and clinical trial support to his institution from Eisai, Bristol Myers Squibb, Exelixis, Genentech/Roche, Merck, Novartis, and Pfizer. M.S. receives grant support and fees for serving on advisory boards for Pfizer, GlaxoSmithKline, Novartis, Bayer, Exelixis, and Roche; and consulting fees, honoraria, and travel support from Pfizer, GlaxoSmithKline, Novartis, Bayer, and Roche. D.J.G. receives honoraria and consulting fees from Sanofi, Exelixis, and Bayer; consulting fees from Merck and Sanofi; grants from Genentech/Roche, Novartis, Astellas, Celldex, and Acerta; and grants and consulting fees from Exelixis, Janssen, Pfizer, Innocrin Pharma, and Bristol Myers Squibb. H.S.P. has received honoraria for advisory work from Ipsen and Eisai. J.-F.M., X.J.M., O.V., X.L., and K.A.C. are employees of and own stock in Pfizer. A.R. receives fees for serving on advisory boards from Pfizer, Novartis, GlaxoSmithKline, Bristol Myers Squibb, AstraZeneca, Merck GA, Merck Sharp & Dohme, Ipsen, and Roche; lecture fees from Pfizer, Novartis, Ipsen, and GlaxoSmithKline; travel support from Pfizer, Novartis, GlaxoSmithKline, Bristol Myers Squibb, Ipsen, Merck GA, and Merck Sharp & Dohme; and grant support from Pfizer, Merck GA, and Novartis.